Literature DB >> 10448811

Syringomyelia and complex regional pain syndrome as complications of multiple sclerosis.

A Das1, K Puvanendran.   

Abstract

OBJECTIVE: To describe a patient from Southeast Asia with the optic-spinal phenotype of multiple sclerosis who developed syringomyelia and resultant complex regional pain syndrome (formerly named reflex sympathetic dystrophy).
DESIGN: Case report.
SETTING: Department of neurology at a tertiary care hospital in the Republic of Singapore. PATIENT: A 53-year-old Chinese woman with a history of optic neuritis developed an episode of left hemiparesis leading to a diagnosis of multiple sclerosis. Serial neuroimaging studies revealed an active demyelinating plaque in the cervical area that later progressed into a syrinx. Over a period of 1 year she also developed signs of sympathetic dysfunction including Horner syndrome of the left eye and complex regional pain syndrome in the left hand.
CONCLUSIONS: A case of the optic-spinal phenotype of multiple sclerosis that is commonly observed in Southeast Asia is described. This characteristically tissue-destructive form of multiple sclerosis resulted in syringomyelia complicated by a complex regional pain syndrome. Possible pathogenic mechanisms for these associations are discussed.

Entities:  

Mesh:

Year:  1999        PMID: 10448811     DOI: 10.1001/archneur.56.8.1021

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  3 in total

1.  Complex Regional Pain Syndrome or Limb Pain: A Plea for a Critical Approach.

Authors:  Astrid Juhl Terkelsen; Frank Birklein
Journal:  J Pain Res       Date:  2022-07-08       Impact factor: 2.832

2.  Syringomyelia presenting with unilateral optic neuropathy: a case report.

Authors:  Qi Zhe Ngoo; Evelyn Li Min Tai; Wan Hazabbah Wan Hitam
Journal:  Int Med Case Rep J       Date:  2017-03-14

3.  LETM presented with causalgia and ensued by sudden death.

Authors:  Rana Alnasser Alsukhni; Yasmin Aboras; Ziena Jriekh; Mahmoud Almalla; Ahmad Sheikh El-Kahwateya
Journal:  BMC Neurol       Date:  2017-01-21       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.